Drugs and Devices

FDA approves Xeljanz for rheumatoid arthritis

On Nov. 6, the U.S. Food and Drug Administration (FDA) approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares